Clik here to view.
MannKind posts mixed Q2
Shares in MannKind Corp. (NSDQ:MNKD) fell slightly this morning after the biopharmaceutical company missed earnings expectations but beat sales estimates on Wall Street with its second quarter results....
View ArticleClik here to view.
Sanofi brings another insulin glargine patent suit against Merck
Sanofi Aventis (NYSE:SNY) yesterday filed another patent lawsuit against Merck Sharp & Dohme Corp. (NYSE:MRK), alleging that Merck’s product infringes upon two patents covering Sanofi’s insulin...
View ArticleClik here to view.
Novo Nordisk shares rise on solid Q2 results
Diabetes drugmaker Novo Nordisk (NYSE:NVO) posted Street-beating second quarter results today, lifting its full-year sales forecast despite lingering concerns relating to U.S. drug pricing pressures....
View ArticleClik here to view.
Aerie’s contract manufacturer faces regulatory hurdle
Aerie Pharmaceuticals (NSDQ:AERI) said today that its contract manufacturer received a complete response letter from the FDA regarding a regulatory application for one of the manufacturer’s own product...
View ArticleClik here to view.
Mylan tumbles on Q2 miss, lowered outlook
Mylan (NSDQ:MYL) shares fell more than -6% this morning after it posted second quarter results that missed analysts’ sales and earnings estimates. The generics-maker announced that it would not include...
View ArticleClik here to view.
Allegro’s diabetic macular edema trial meets primary endpoint
Privately-held biotech Allegro Ophthalmics said today that its Del Mar Phase IIb stage 2 trial met its primary endpoint. The study assessed Luminate as a sequential therapy or combo therapy in 80...
View ArticleClik here to view.
Clearside Biomedical misses EPS estimate in Q2
Shares in Clearside Biomedical (NSDQ:CLSD) fell slightly today after the biopharmaceutical company missed earnings expectations on Wall Street with its second quarter results. The Alpharetta, Ga.-based...
View ArticleClik here to view.
Ocular’s new CEO to ‘aggressively’ seek partnerships
Since the start of June, Ocular Therapeutix‘s (NSDQ:OCUL) stock price has fallen more than -45%. The company’s founder and chief executive, Amar Swahney, has stepped down, assuming the role of...
View ArticleClik here to view.
Inovio tops Q2 sales estimate by $4m
Shares in Inovio Pharmaceuticals (NSDQ:INO) rose today after the pharmaceutical company beat expectations on Wall Street with its second quarter results. The Plymouth Meeting, Penn.-based company...
View ArticleClik here to view.
Liposomes triggered by ultrasound enable targeted pain-relief
Researchers at Boston Children’s Hospital have developed a technology to non-invasively trigger the release of nerve-blocking agents, helping to provide targeted pain-relief to patients as an...
View ArticleClik here to view.
BioDelivery Sciences beats Q2 rev estimates, misses on EPS
Shares in BioDelivery Sciences International (NSDQ:BDSI) fell today after the pharmaceutical company beat sales estimates but missed earnings expectations on Wall Street with its second quarter...
View ArticleClik here to view.
Titan Pharmaceuticals misses estimates in Q2
Shares in Titan Pharmaceuticals (NSDQ:TTNP) fell yesterday after the pharmaceutical company missed expectations on Wall Street with its second quarter results. The San Francisco, Calif.-based company...
View ArticleClik here to view.
Study: Abuse-deterrent opioids are costly and unproven
In an attempt to curb the harrowing opioid crisis in America, drugmakers have developed what they tout as “abuse-deterrent” pain-killers – opioid formulations that are designed to prevent users from...
View ArticleClik here to view.
IntelGenx misses Q2 sales, earnings estimates
Drug delivery company IntelGenx (CVE:IGX) missed expectations on Wall Street yesterday with its second quarter results. The Quebec-based company posted a net loss of -$550,000 on sales of $1.1 million...
View ArticleClik here to view.
MIT researchers developing device to pump drugs to the brain
Credit: Denis Paiste/Materials Processing Center Researchers at the Massachusetts Institute of Technology are developing a pump to deliver drugs directly to the brain. Alejandro Aponte, a mechanical...
View ArticleClik here to view.
Trump declares national emergency over opioid epidemic
President Trump said yesterday that he is preparing to declare the opioid epidemic a national emergency. This is a reversal from an announcement made earlier this week by Health and Human Services...
View ArticleClik here to view.
SteadyMed tops Q2 sales, EPS estimates
Shares in SteadyMed (NSDQ:STDY) fell today after the pharmaceutical company beat sales expectations on Wall Street with its second quarter results, but missed EPS estimates. The San Ramon, Calif.-based...
View ArticleClik here to view.
Merck CEO Frazier leaves Trump council
Merck (NYSE:MRK) announced today that chief executive Kenneth Frazier plans to resign from President Donald Trump’s American Manufacturing Council, citing the president’s mild-mannered response to a...
View ArticleClik here to view.
Pavmed beats Q2 EPS by a penny
Medical device maker Pavmed Inc. (NSDQ:PAVM) topped expectations on Wall Street with its second quarter results today. The New York-based company posted a net loss of -$989,707, or -8¢ per share, for...
View ArticleClik here to view.
Ophthotech eye-drug trial fails to meet primary endpoint
Shares in Ophthotech (NSDQ:OPHT) dipped to $2.46 apiece this morning after the company announced that its Phase III wet age-related macular degeneration trial failed to meet its primary endpoint. The...
View Article